$76MSeries B, 7 January 2026
Funds clinical studies including Phase 1 of MTX-439 and Phase 2a of MTX-474 in systemic sclerosis.
- Amount
- $76M
- Stage
- Series B
- Announced
- 7 January 2026
- Lead
- Amplitude Ventures
- Other investors
- ICG, Longwood Fund, Asahi Kasei Pharma Ventures, Alexandria Venture Investments
- Use of funds
- Funds clinical studies including Phase 1 of MTX-439 and Phase 2a of MTX-474 in systemic sclerosis.
- Checked
- Announced by the company
- Source
- Mediar Therapeutics announces oversubscribed $76M Series B prnewswire.com